Wealth Enhancement Advisory Services LLC Makes New Investment in Becton, Dickinson and Company (NYSE:BDX)

Posted by Defense World Staff on Jul 13th, 2023

Wealth Enhancement Advisory Services LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,243 shares of the medical instruments supplier’s stock, valued at approximately $555,000.

Several other large investors have also recently bought and sold shares of the company. Fairfield Bush & CO. acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $114,000. Sequoia Financial Advisors LLC lifted its stake in shares of Becton, Dickinson and Company by 11.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock valued at $778,000 after purchasing an additional 297 shares during the period. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 8.8% in the 1st quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $368,000 after purchasing an additional 112 shares during the period. Zions Bancorporation N.A. increased its position in shares of Becton, Dickinson and Company by 13.0% in the 1st quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock valued at $134,000 after buying an additional 58 shares in the last quarter. Finally, Mather Group LLC. increased its position in shares of Becton, Dickinson and Company by 26.0% in the 1st quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock valued at $358,000 after buying an additional 278 shares in the last quarter. Institutional investors and hedge funds own 85.57% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $258.66 on Thursday. The stock has a 50-day moving average price of $253.07 and a two-hundred day moving average price of $250.17. The stock has a market cap of $73.46 billion, a PE ratio of 48.53, a price-to-earnings-growth ratio of 2.09 and a beta of 0.57. The company has a current ratio of 1.31, a quick ratio of 0.81 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 1 year low of $215.90 and a 1 year high of $269.06.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $2.86 EPS for the quarter, topping analysts’ consensus estimates of $2.75 by $0.11. Becton, Dickinson and Company had a net margin of 8.59% and a return on equity of 12.98%. The company had revenue of $4.82 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the prior year, the business posted $3.18 EPS. The company’s quarterly revenue was up 1.5% on a year-over-year basis. Equities analysts forecast that Becton, Dickinson and Company will post 12.19 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 30th. Stockholders of record on Friday, June 9th were paid a dividend of $0.91 per share. The ex-dividend date of this dividend was Thursday, June 8th. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.41%. Becton, Dickinson and Company’s dividend payout ratio is 68.29%.

Wall Street Analyst Weigh In

A number of research firms recently commented on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Evercore ISI lowered their price objective on shares of Becton, Dickinson and Company from $280.00 to $275.00 and set an “outperform” rating for the company in a research report on Tuesday, April 4th. Piper Sandler upgraded shares of Becton, Dickinson and Company from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $260.00 to $290.00 in a research report on Friday, May 5th. Finally, Barclays upped their price objective on shares of Becton, Dickinson and Company from $282.00 to $284.00 in a research report on Monday, May 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average price target of $276.78.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.